Shares of Teleflex Inc. (NYSE:TFX) have been assigned a consensus recommendation of “Buy” from the ten ratings firms that are covering the stock. Two equities research analysts have rated the stock with a hold recommendation, seven have issued a buy recommendation and one has assigned a strong buy recommendation to the company. The average twelve-month price target among brokerages that have updated their coverage on the stock in the last year is $173.38.
Several research firms have commented on TFX. Barclays PLC upped their price objective on shares of Teleflex from $183.00 to $185.00 and gave the company an “overweight” rating in a report on Friday, July 29th. Jefferies Group upped their price target on Teleflex from $157.00 to $185.00 and gave the company a “hold” rating in a research report on Friday, July 29th. Leerink Swann upped their price target on Teleflex from $183.00 to $190.00 and gave the company a “market perform” rating in a research report on Friday, July 29th. Finally, Zacks Investment Research upgraded Teleflex from a “hold” rating to a “buy” rating and set a $192.00 price target on the stock in a research report on Wednesday, June 29th.
Shares of Teleflex (NYSE:TFX) traded up 0.77% during trading on Thursday, hitting $166.64. 103,450 shares of the stock traded hands. Teleflex has a 1-year low of $123.79 and a 1-year high of $188.79. The stock has a market cap of $7.34 billion, a price-to-earnings ratio of 29.58 and a beta of 0.83. The stock has a 50 day moving average price of $175.50 and a 200-day moving average price of $170.45.
Teleflex (NYSE:TFX) last released its quarterly earnings data on Thursday, July 28th. The medical technology company reported $1.89 EPS for the quarter, beating the Thomson Reuters’ consensus estimate of $1.74 by $0.15. The business had revenue of $473.60 million for the quarter, compared to the consensus estimate of $468.40 million. Teleflex had a net margin of 14.89% and a return on equity of 15.59%. The company’s revenue was up 4.8% compared to the same quarter last year. During the same period in the prior year, the firm earned $1.42 earnings per share. Equities analysts forecast that Teleflex will post $7.33 EPS for the current year.
The business also recently disclosed a quarterly dividend, which was paid on Thursday, September 15th. Investors of record on Monday, August 15th were given a $0.34 dividend. This represents a $1.36 annualized dividend and a dividend yield of 0.82%. The ex-dividend date of this dividend was Thursday, August 11th. Teleflex’s dividend payout ratio (DPR) is 24.11%.
Hedge funds and other institutional investors have recently bought and sold shares of the company. Tower Research Capital LLC TRC purchased a new stake in shares of Teleflex during the second quarter valued at about $118,000. Huntington National Bank raised its stake in shares of Teleflex by 6.5% in the second quarter. Huntington National Bank now owns 820 shares of the medical technology company’s stock valued at $145,000 after buying an additional 50 shares in the last quarter. Checchi Capital Advisers LLC raised its stake in shares of Teleflex by 0.8% in the second quarter. Checchi Capital Advisers LLC now owns 837 shares of the medical technology company’s stock valued at $148,000 after buying an additional 7 shares in the last quarter. Welch & Forbes LLC purchased a new stake in shares of Teleflex during the second quarter valued at about $204,000. Finally, Broderick Brian C purchased a new stake in shares of Teleflex during the second quarter valued at about $207,000. Institutional investors own 93.77% of the company’s stock.